Showing results (1-10 of 209) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2015
Cancer Immunotherapy: More Is (Much) BetterYosef Yarden, Michael Sela
Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor TherapyGeorg Mahlknecht, Michael Sela, Yosef Yarden
Physiology (Bethesda, Md.)|May 1, 2010
Roles for growth factors in cancer progressionEsther Witsch, Michael Sela, Yosef Yarden
British Journal of Pharmacology|February 3, 2016
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, et al.
Molecular Oncology|April 23, 2009
Cancer therapeutic antibodies come of age: targeting minimal residual diseaseTsipi Ben-Kasus, Bilha Schechter, Michael Sela, et al.
Biochemical and Biophysical Research Communications|August 7, 2015
Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor bindingGeorg Mahlknecht, Ruth Maron, Bilha Schechter, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 17, 2009
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosisTsipi Ben-Kasus, Bilha Schechter, Sara Lavi, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 1, 2013
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growthGeorg Mahlknecht, Ruth Maron, Maicol Mancini, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 5, 2013
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2Ruth Maron, Bilha Schechter, Maicol Mancini, et al.
Translational Oncology|October 4, 2011
Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 AbundanceAnna Emde, Georg Mahlknecht, Kerstin Maslak, et al.
Pageof 21